{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:18:41Z","timestamp":1783635521707,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-070"],"award-info":[{"award-number":["2021-I2M-1-070"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>As a global health problem, liver fibrosis still does not have approved treatment. It was proved that N-(3,4,5-trichlorophenyl)-2(3-nitrobenzenesulfonamide) benzamide (IMB16-4) has anti-hepatic fibrosis activity. However, IMB16-4 displays poor water solubility and poor bioavailability. We are devoted to developing biodegraded liposome-coated polymeric nanoparticles (LNPs) as IMB16-4 delivery systems for improving aqueous solubility, cellular uptake, and anti-fibrotic effects. The physical states of IMB16-4\u2212LNPs were analyzed using a transmission electron microscope (TEM), high-performance liquid chromatography (HPLC), Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD) and differential scanning calorimeter (DSC). The results show that IMB16-4\u2212LNPs increased the drug loading compared to liposomes and enhanced cellular uptake behavior compared with IMB16-4\u2212NPs. In addition, IMB16-4\u2212LNPs could repress the expression of hepatic fibrogenesis-associated proteins, indicating that IMB16-4\u2212LNPs exhibited evident anti-fibrotic effects.<\/jats:p>","DOI":"10.3390\/molecules27123738","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T22:37:20Z","timestamp":1655073440000},"page":"3738","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Established Liposome-Coated IMB16-4 Polymeric Nanoparticles (LNPs) for Increasing Cellular Uptake and Anti-Fibrotic Effects In Vitro"],"prefix":"10.3390","volume":"27","author":[{"given":"Xia","family":"Niu","sequence":"first","affiliation":[{"name":"Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-3691","authenticated-orcid":false,"given":"Yanan","family":"Meng","sequence":"additional","affiliation":[{"name":"Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-6286","authenticated-orcid":false,"given":"Guiling","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Medicinal Biotechnology, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(14)60121-5","article-title":"Liver cirrhosis","volume":"383","author":"Tsochatzis","year":"2014","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: The major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Roehlen, N., Crouchet, E., and Baumert, T.F. (2020). Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells, 9.","DOI":"10.3390\/cells9040875"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/hep.30965","article-title":"A Deactivation Factor of Fibrogenic Hepatic Stellate Cells Induces Regression of Liver Fibrosis in Mice","volume":"71","author":"Nakano","year":"2020","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2018.05.021","article-title":"Oral vitamin-A-coupled valsartan nanomedicine: High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence","volume":"283","author":"Shalaby","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000343852","article-title":"From Cirrhosis to Hepatocellular Carcinoma: New Molecular Insights on Inflammation and Cellular Senescence","volume":"2","author":"Ramakrishna","year":"2013","journal-title":"Liver Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"001","DOI":"10.1055\/s-0036-1597816","article-title":"Regression of Liver Fibrosis","volume":"37","author":"Campana","year":"2017","journal-title":"Semin. Liver Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3350\/cmh.2017.0078","article-title":"Histopathological evaluation of liver fibrosis and cirrhosis regression","volume":"23","author":"Lo","year":"2017","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_11","first-page":"36","article-title":"Fibrogenesis, hepatic stellate cells and the immune system","volume":"135","author":"Taimr","year":"2004","journal-title":"Immunol. Dis. Liver Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1111\/j.1440-1746.2006.04658.x","article-title":"Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis","volume":"22","author":"Kisseleva","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(99)00418-5","article-title":"Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells","volume":"378","author":"Inoue","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/gast.1996.v110.pm8608892","article-title":"Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver","volume":"110","author":"Benyon","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1172\/JCI1018","article-title":"Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors","volume":"102","author":"Iredale","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_16","first-page":"S8","article-title":"N-Cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1","volume":"3","author":"Murphy","year":"2004","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11069","DOI":"10.1074\/jbc.M111490200","article-title":"Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: Implications for reversibility of liver fibrosis","volume":"277","author":"Murphy","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1111\/j.1440-1746.2007.04961.x","article-title":"Role of adipocytokines in hepatic fibrogenesis","volume":"22","author":"Ikejima","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ra77","DOI":"10.1126\/scisignal.2004060","article-title":"The p130 Isoform of Angiomotin Is Required for Yap-Mediated Hepatic Epithelial Cell Proliferation and Tumorigenesis","volume":"6","author":"Yi","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1097\/CM9.0000000000000835","article-title":"Regression of liver fibrosis: Evidence and challenges","volume":"133","author":"Sun","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/j.clinre.2015.06.011","article-title":"New therapies for hepatic fibrosis","volume":"39","author":"Koyama","year":"2015","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Traber, P.G., Chou, H., Zomer, E., Hong, F., Klyosov, A., Fiel, M.-I., and Friedman, S.L. (2013). Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075361"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fimmu.2020.00218","article-title":"Targeting of Hepatic Macrophages by Therapeutic Nanoparticles","volume":"11","author":"Colino","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000445269","article-title":"New Developments on the Treatment of Liver Fibrosis","volume":"34","author":"Koyama","year":"2016","journal-title":"Dig. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1254\/fpj.154.203","article-title":"Mechanisms of hepatic stellate cell activation as a therapeutic target for the treatment of non-alcoholic steatohepatitis","volume":"154","author":"Tsuchida","year":"2019","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Niu, X., Wang, X., Niu, B., Wang, Y., He, H., and Li, G. (2022). New IMB16-4 Nanoparticles Improved Oral Bioavailability and Enhanced Anti-Hepatic Fibrosis on Rats. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010085"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Niu, X., Wang, X., Niu, B., Li, G., Yang, X., Wang, Y., and Li, G. (2021). Novel IMB16-4 Compound Loaded into Silica Nanoparticles Exhibits Enhanced Oral Bioavailability and Increased Anti-Liver Fibrosis In Vitro. Molecules, 26.","DOI":"10.3390\/molecules26061545"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.drudis.2018.05.033","article-title":"Lipid\u2013polymer hybrid nanocarrier-mediated cancer therapeutics: Current status and future directions","volume":"23","author":"Garg","year":"2018","journal-title":"Drug Discov. Today"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ejpb.2013.07.002","article-title":"Lipid\u2013polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review","volume":"85","author":"Hadinoto","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2217\/17435889.2.1.85","article-title":"Liposome\u2013nanoparticle hybrids for multimodal diagnostic and therapeutic applications","volume":"2","author":"Kostarelos","year":"2007","journal-title":"Nanomedicine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.nano.2012.11.010","article-title":"Core\u2013shell-type lipid\u2013polymer hybrid nanoparticles as a drug delivery platform","volume":"9","author":"Mandal","year":"2013","journal-title":"Nanomedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1039\/c2nr32880a","article-title":"Lipid-enveloped hybrid nanoparticles for drug delivery","volume":"5","author":"Tan","year":"2013","journal-title":"Nanoscale"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1039\/C3CS60299K","article-title":"Merging the best of both worlds: Hybrid lipid-enveloped matrix nanocomposites in drug delivery","volume":"43","author":"Raemdonck","year":"2014","journal-title":"Chem. Soc. Rev."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/12\/3738\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:27:31Z","timestamp":1760138851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/12\/3738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["molecules27123738"],"URL":"https:\/\/doi.org\/10.3390\/molecules27123738","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}